---
schema_version: "secwatch.filing_event.v1"
accession: "0001636651-25-000017"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:30:35.377323+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics stockholders approve 3 proposals at special meeting including authorized share increase to 315M

## Summary
- Approved amendment to increase authorized common shares from 125M to 315M: 34.2M for, 1.5M against, 2.4M abstain.
- Approved issuance of shares upon conversion of Series B Preferred and exercise of Series A/B Warrants: 34.3M for, 1.3M against, 2.5M abstain.
- Approved issuance of securities to CEO Jeremy Levin under Oct 2, 2025 Securities Purchase Agreement: 34.3M for, 1.2M against, 2.5M abstain.
- Special meeting held Dec 11, 2025; quorum 38.0M of 71.2M outstanding shares (53.42%).

## SEC filing metadata
- accession: 0001636651-25-000017
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000163665125000017/0001636651-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000163665125000017/ovid-20251211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636651-25-000017
- JSON: https://secwatch.observer/filing/0001636651-25-000017.json
- Plain text: https://secwatch.observer/filing/0001636651-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.